Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.31 |
| ▸ | HTR3B | O95264 | 2/20 | 0.31 |
| ▸ | HTR3A | P46098 | 2/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102848 | 0.82 | CES2 (0.40) | TSHRMAPK1KIF11NOS3NOS2 | |
| SCHEMBL23174652 | 0.79 | CES2 (0.39) | TSHRMAPK1KIF11NOS3NOS2 | |
| SCHEMBL27886103 | 0.79 | CES2 (0.39) | TSHRMAPK1KIF11NOS3NOS2 | |
| SCHEMBL29121446 | 0.79 | CES2 (0.39) | TSHRMAPK1KIF11NOS3NOS2 | |
| SCHEMBL28642337 | 0.79 | CES2 (0.39) | TSHRMAPK1KIF11NOS3NOS2 | |
| SCHEMBL28493618 | 0.76 | POLB (0.39) | MAPK1POLBGAAALDH1A1PKM | |
| SCHEMBL28585089 | 0.73 | CES2 (0.34) | TSHRALDH1A1HTR3EHTR3BHTR3A | |
| SCHEMBL596022 | 0.73 | RAPGEF4 (0.35) | TSHRKIF11ALDH1A1MAPT | |
| SCHEMBL147083 | 0.73 | AHR (0.36) | TSHRALDH1A1HPGDMAPTPLAU | |
| Magnesium Chloride Anhydrous SCHEMBL29163555 | 0.73 | CES2 (0.34) | TSHRALDH1A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746411-B | Substituted tricyclic compounds | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | claimed |
| WO-2023178130-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | claimed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| CN-114746411-B | Substituted tricyclic compounds | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-117580836-A | Pyrimidine ring structure derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023178130-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-116648250-A | Novel quinazoline derivatives as SOS1 inhibitors and uses thereof | 韩美药品株式会社 | 2023-08-25 | — | — | CN | disclosed |
| CN-116568689-A | Polycyclic pyrimidine derivative as SOS1 inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-114746411-A | Substituted tricyclic compounds | 印度鲁宾有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-27 | — | — | US | disclosed |
| US-20020111482-A1 | Method for producing palladium complex compound | CENTRAL GLASS COMPANY, LIMITED | 2002-08-15 | — | — | US | disclosed |
| WO-2002050019-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2002-06-27 | — | — | WO | disclosed |
| US-6337335-B1 | ENZYME INHIBITORS FOR AUTOIMMUNE DISEASES, TRANSPLANT REJECTION, GRANT VERSUS HOST DISEASE, HYPERPROLIFERATIVE DISORDERS AND DISEASES IN WHICH CELLS RECEIVE PRO-INFLAMMATORY SIGNALS. | CELLTECH THERAPEUTICS LIMITED (GB) | 2002-01-08 | — | — | US | disclosed |
| US-6303543-B1 | Diaryl ethers and processes for their preparation and herbicidal and desiccant compositions containing them | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6121201-A | HETEROARYL SUBSTITUTED HALO-PYRAZOLE SUBSTITUTED DIARYL ETHERS OR THIOETHERS | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-1008601-A2 | Method for producing palladium complex compound | Central Glass Company, Limited (JP) | 2000-06-14 | — | — | EP | disclosed |
| US-6048866-A | Substituted 2-anilinopryimidines useful as protein kinase inhibitors | CELLTECH THERAPEUTICS, LIMITED (GB) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | TSHR 4233/4885MAPK1 218/4885KIF11 3118/4885 |
| US-20020111482-A1 | Method for producing palladium complex compound | PDCD1LG2, CD274, PDCD1 | TSHR 377/4885MAPK1 1450/4885KIF11 828/4885 |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | TSHR 1900/4885MAPK1 200/4885KIF11 1679/4885 |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | TSHR 1031/4885MAPK1 893/4885KIF11 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.